| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Guancydine targets the sympathetic nervous system and vascular smooth muscle. It reduces arterial pressure primarily through peripheral vasodilation and diminished sympathetic outflow. The compound inhibits enzymes involved in the synthesis of pressor agents, contributing to its antihypertensive effects.
|
|---|---|
| ln Vitro |
In vitro, Guancydine exhibits vasodilatory activity by relaxing vascular smooth muscle. Its mechanism involves modulation of sympathetic neurotransmission and direct effects on vascular tone. Detailed in vitro activity data including IC50 values are not extensively reported in the available literature.
|
| ln Vivo |
In vivo, Guancydine is an antihypertensive agent that lowers blood pressure in animal models and human subjects. It reduces arterial pressure through peripheral vasodilation and diminished sympathetic outflow. It was historically used to investigate mechanisms of blood pressure regulation and sympathetic nervous system control.
|
| Enzyme Assay |
In vitro receptor binding assays for Guancydine are not extensively characterized. As a guanidine derivative, it may interact with adrenergic receptors or ion channels involved in vascular tone regulation. Radioligand binding studies using vascular tissue preparations or recombinant receptors could be performed to assess binding affinity.
|
| Cell Assay |
Cellular assays for Guancydine are conducted using vascular smooth muscle cells. Cells are treated with the compound at various concentrations (1-100 uM), and vasodilatory effects are assessed by measuring changes in intracellular calcium levels or cell contraction. Endothelial function may also be evaluated.
|
| Animal Protocol |
In vivo animal studies for Guancydine are conducted in hypertensive rat models. The compound is administered via oral or intravenous routes at doses determined from pharmacokinetic studies. Blood pressure is measured by tail-cuff plethysmography or telemetry. Heart rate and other hemodynamic parameters are monitored. Efficacy is assessed by reduction in mean arterial pressure.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Guancydine have not been extensively characterized. The compound has a molecular weight of 154.21 and formula C7H14N4. It is a solid compound typically used in research settings. Bioavailability, half-life, and metabolic pathway data are not available in the literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for Guancydine are limited. As an antihypertensive agent, potential adverse effects may include hypotension, dizziness, and sympathetic nervous system modulation. Standard toxicology assessments would be required for therapeutic development. The compound is for research use only.
|
| References | |
| Additional Infomation |
Guancidine is a type of guanidine compound.
Guancydine (Guancidine) is a research-use compound not approved for clinical therapeutic applications in most regions. It was historically investigated as an antihypertensive agent. It is used in pharmacological research to study blood pressure regulation, sympathetic nervous system control, and guanidine derivative pharmacology. The compound is for research use only and not for human therapeutic application. |
| Molecular Formula |
C7H14N4
|
|---|---|
| Molecular Weight |
154.21300
|
| Exact Mass |
154.122
|
| CAS # |
1113-10-6
|
| PubChem CID |
14211
|
| Appearance |
White to off-white solid powder
|
| Density |
1.02g/cm3
|
| Boiling Point |
239.3ºC at 760 mmHg
|
| Flash Point |
98.5ºC
|
| Vapour Pressure |
0.0404mmHg at 25°C
|
| Index of Refraction |
1.504
|
| LogP |
1.651
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
11
|
| Complexity |
196
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VZVGEDRCVUKSEL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H14N4/c1-4-7(2,3)11-6(9)10-5-8/h4H2,1-3H3,(H3,9,10,11)
|
| Chemical Name |
1-cyano-2-(2-methylbutan-2-yl)guanidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 125 mg/mL (~810.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (13.49 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (13.49 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (13.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.4847 mL | 32.4233 mL | 64.8466 mL | |
| 5 mM | 1.2969 mL | 6.4847 mL | 12.9693 mL | |
| 10 mM | 0.6485 mL | 3.2423 mL | 6.4847 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
